Hutson Nancy J's Form 4/A amendment
AmendedPhaseBio Pharmaceuticals Inc (PHAS) · filed May 20, 2022
- Accession no.
- 0001169245-22-000067
- Filed
- May 20, 2022
- Trade date
- Aug 18, 2021
- Filing delay
- 275 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Aug 19, 2021
This filing lists 1 non-derivative transaction. Open-market purchases total $9.24K. It was filed 275 days after the trade.
This amendment replaces 0001169245-21-000083 (filed Aug 19, 2021).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Hutson Nancy JCIK 0001379222 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2021 | Common Stock | PPurchaseAcquired | +3,000 | $3.08F1 | +$9,240 | 4,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.07 to $3.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4.
Referenced by the price of 1 transaction in Table I.
- F2
Amended to report direct share ownership.